Abbott numbers hint at strong AbbVie beginning; Teva's Nuvigil fails bipolar depression trial;

@FiercePharma: Which pharma brands do docs trust most? Advair (GSK), Humira (AbbVie), Enbrel (Amgen/Pfizer) among them, says survey. More | Follow @FiercePharma

 @AlisonBFierce: Protein Sciences uses cells from the ovaries of armyworms to make the active ingredient in Flublok. Story | Follow @AlisonBFierce

> Abbott Laboratories' ($ABT) fourth-quarter results offer optimism for the success of its newly spun-off pharma unit, AbbVie ($ABBV); lead product Humira saw a 23% sales gain, and other brands performed well. Report

> Nuvigil, the wakefulness drug from Teva Pharmaceutical Industries ($TEVA), failed its second trial in patients with bipolar depression, after hitting goal in its first depression trial. Report

> French drugmaker Pierre Fabre failed to persuade U.K. gatekeepers that its drug Javior is cost-effective as a bladder cancer treatment. Report

> Massachusetts is reviewing its policy on generic drug substitution to prepare for biosimilar versions of biotech drugs. Report

> India's pharma market is expected to grow at 14% to 17% annually through 2016, putting it among the top 5 emerging drug markets. Report

> Amgen ($AMGN) is one of the U.S. companies that is keeping cash declared as "indefinitely invested" overseas in U.S. bank accounts. Report (sub. req.)

Medical Device News

 @FierceMedDev: Quest posts 24% Q4 profit drop amid restructuring. More | Follow @FierceMedDev

 @DamianFierce: $JNJ knew about hip implant failure concerns two years before recalling the all-metal devices. News | Follow @DamianFierce

> Abbott faces slumping stent sales in drug-free future. Report

> After FDA ban, Hospira creeps back into the infusion game with Q Core deal. Story

Biotech News

 @FierceBiotech: Allergan bags migraine drug in $1B MAP Pharma buyout. More | Follow @FierceBiotech

@JohnCFierce: Hugin's bold promises on future Celgene revenue face first test with Abraxane pancreatic cancer OS data. News | Follow @JohnCFierce

@RyanMFierce: I'm thinking, at best, Jimenez and Reinhardt are frienemies. Should be interesting to see how this pharma marriage goes. | Follow @RyanMFierce

> Novartis dumps a long-faded $500M pact with Cytos. Story

> Watson beefs up R&D effort with $305M women's health buyout. Report

Drug Delivery News

> Amunix hooks Janssen with its XTEN delivery technology. Story

> Study: Biotronik's dissolving stent deemed safe, falls short of Abbott's Absorb. Article

> Phosphagenics' oxymorphone pain patch close to clinic. Report

> Nanosphere foam delivers drugs to the bladder. News

Biomarkers News

> Researcher spotlights new biomarker for gliomas. Item

> U.K.-based International Diagnostics Centre brings global diagnostics R&D together. Story

> Bill Gates added to investor list in backing genomic tests startup. Report

> Onconova teams with GVK to take cancer biomarkers to IND phase. News

And Finally... Can a dieticians' trade group be objective about nutrition when it's sponsored by Big Food? Report (sub. req.)

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.